After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Patient Chart Dynamix™ is an independent, data-driven service that unveils real-world patient management trends via large-scale patient chart audits. Designed to quantify practice patterns, measure ...

Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...

Subjects with generalized cutaneous reactions (PMLE-like and sting/itch) and those who experienced sun-induced systemic symptoms of joint pain, weakness, fatigue or headaches, tended to have more ...

The foregoing results lead to the conclusion that patients with disseminated lupus erythematosus and some patients with rheumatoid arthritis present a delayed cutaneous hypersensitivity when ...

Deucravacitinib inhibits tyrosine kinase 2, which is implicated in cutaneous lupus erythematosus’s pathophysiology. Deucravacitinib yielded improvements in disease severity by week 16.

Extra-cutaneous symptoms that suggest systemic involvement ... The patient is a 47-year-old male with a 6-year history of systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome.

Most people with lupus have some type of skin problems, such as a lupus rash or other changes to the skin. Based on the type ...

In a small phase II trial of cutaneous lupus erythematosus (CLE), patients treated with the TYK2 inhibitor had as much as 50% improvement in disease status at week 16. Adverse events in both ...

More information: Henry W. Chen et al, Incidence and Prevalence of Atherosclerotic Cardiovascular Disease in Cutaneous Lupus ...

Of note are the derivation of the term lupus and the clinical descriptions of the cutaneous lesions of lupus vulgaris, lupus profundus, discoid lupus, and the photosensitive nature of the malar or ...